Compare APM & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APM | HKPD |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United Kingdom | Hong Kong |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 6.9M |
| IPO Year | 2018 | N/A |
| Metric | APM | HKPD |
|---|---|---|
| Price | $0.78 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.9K | ★ 35.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.58 |
| 52 Week High | $4.47 | $2.74 |
| Indicator | APM | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 47.89 |
| Support Level | $0.74 | $0.64 |
| Resistance Level | $0.86 | $0.70 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 26.07 | 75.75 |
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.